INFO	Title	Acute Lymphoblastic Leukemia (ALL) Data Dictionary
INFO	Name	all_v1.0
INFO	Release Notes	https://github.com/chicagopcdc/d4cg-modeling/tree/main/pcdc/data-dictionaries/all/all_v1.0
INFO	Parent Data Model	pcdc_v1.8
INFO	License	Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/)
INFO	D4CG Data Modeling Wiki	https://docs.pedscommons.org/
INFO	Disease Consortium Information	https://commons.cri.uchicago.edu/pcdc/
INFO	Description	Acute Lymphoblastic Leukemia (ALL) Data Dictionary
INFO	Total Variables	120

RowType	VariableName	DataType	Tier	VariableDescription	VariableCode	PermissibleValue	ValueDescription	ValueCode	ImplementationNotes	Mappings

DD	Protocol									
TD	Subject Identifier
TG	Will be included in every table
VD	PCDC_SUBJECT_ID	String	Mandatory	A unique subject id assigned by the PCDC. Any given individual person will have only one PCDC_SUBJECT_ID regardless of the number of studies in which they appear. If an individual person is on studies from more than one contributor, they may have more than one HONEST_BROKER_SUBJECT_IDs assigned to them by the contributors, but will be resulted to a single PCDC_SUBJECT_ID by PCDC staff.	ncit:C69256	_undefined_	_undefined_	_undefined_


DD	Protocol
TD	Subject Characteristics
TG	One row per subject per study
VD	HONEST_BROKER_SUBJECT_ID	String	Mandatory	The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	ncit:C168949	_undefined_	_undefined_	_undefined_
VD	DATA_CONTRIBUTOR_ID	Code	Mandatory	An identifier assigned to a data contributor.	ncit:C168950	_undefined_	_undefined_	_undefined_
PD						COG	Children's Oncology Group. An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.	ncit:C39353
VD	STUDY_ID	Code	Mandatory	A sequence of characters used to identify, name, or characterize the study.	ncit:C83082	_undefined_	_undefined_	_undefined_
PD						AALL0331	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. Children’s Oncology Group (COG) AALL0331 tested whether intensified postinduction therapy that improves survival in children with high-risk B-cell acute lymphoblastic leukemia (ALL) would also improve outcomes for those with standard-risk (SR) ALL. (Maloney KW, Devidas M, Wang C, et al. Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. J Clin Oncol. 2020;38(6):602-612. doi:10.1200/JCO.19.01086.)	ncit:C178095
PD						AALL0232	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. Children’s Oncology Group study AALL0232 tested two interventions to improve survival. Between January 2004 and January 2011, AALL0232 enrolled 3,154 participants 1 to 30 years old with newly diagnosed high-risk B-acute lymphoblastic leukemia. By using a 2 × 2 factorial design, 2,914 participants were randomly assigned to receive dexamethasone (14 days) versus prednisone (28 days) during induction and high-dose methotrexate versus Capizzi escalating-dose methotrexate plus pegaspargase during interim maintenance 1. (Larsen EC, Devidas M, Chen S, et al. Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. J Clin Oncol. 2016;34(20):2380-2388. doi:10.1200/JCO.2015.62.4544)	ncit:C178065
PD						AALL0434	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. Nelarabine is effective in inducing remission in patients with relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) but has not been fully evaluated in those with newly diagnosed disease. From 2007 to 2014, Children’s Oncology Group trial AALL0434 enrolled 1,562 evaluable patients with T-ALL age 1-31 years who received the augmented Berlin-Frankfurt-Muenster (ABFM) regimen with a 2 × 2 pseudo-factorial randomization to receive escalating-dose methotrexate (MTX) without leucovorin rescue plus pegaspargase (C-MTX) or high-dose MTX (HDMTX) with leucovorin rescue. (Dunsmore KP, Winter SS, Devidas M, et al. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020;38(28):3282-3293. doi:10.1200/JCO.20.00256)	ncit:C178066
PD						AALL08B1	Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study. A total of 65 patients enrolled on the Children's Oncology Group (COG) study AALL08B1 were identified for study, as cytogenetic and FISH studies had also been performed on these patients, with a central review of those results available for comparison. (Baughn LB, Biegel JA, South ST, et al. Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study. Cancer Genet. 2015;208(1-2):1-18. doi:10.1016/j.cancergen.2014.11.003)	ncit:C178067
PD						AALL03B1	Classification of Acute Lymphoblastic Leukemia is a COG study from 2003-2011. This clinical trial is studying risk-group classification of patients with newly diagnosed acute lymphoblastic leukemia. Developing a risk-group classification guide may help doctors assign patients with newly diagnosed acute lymphoblastic leukemia to treatment clinical trials. (ClinicalTrials.gov Identifier: NCT00482352)	ncit:C178068
VD	AGE_AT_ENROLLMENT	Number	Mandatory	The age (in days) when the subject enrolled in the study.	ncit:C168843	_undefined_	_undefined_	_undefined_
VD	TREATMENT_ARM	Code	Mandatory	A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.	ncit:C15538	_undefined_	_undefined_	_undefined_
VD	ENROLLED_STATUS	Code	Optional	This variable indicates if the subject was enrolled in the study, or if the subject was not enrolled in the study but received treatment per the study's protocol.	ncit:C168298	_undefined_	_undefined_	_undefined_	Note: refers to if subject was enrolled in the study, or subject was not enrolled in the study but received treatment per the study's protocol.
PD						Enrolled	The study subject is enrolled.	ncit:C142715
PD						Not Enrolled	The study subject is not enrolled.	ncit:C168929


DD	Protocol
TD	Disease Phase Timing
TG	One row per subject per disease phase(s)
VD	DISEASE_PHASE	Code	Mandatory	The stage or period of an individual's disease.	ncit:C168878	_undefined_	_undefined_	_undefined_	Note: Disease phase could be "Initial Diagnosis" phase, a "Relapse" phase, or a "Progression" phase.
PD						Initial Diagnosis	The first diagnosis of the individual's condition.	ncit:C156813
PD						Relapse	The return of a disease after a period of remission.	ncit:C38155
PD						Refractory	Not responding to treatment.	ncit:C38014
VD	DISEASE_PHASE_NUMBER	Number	Mandatory	The number of the disease phase.	ncit:C173258	_undefined_	_undefined_	_undefined_
VD	AGE_AT_DISEASE_PHASE	Number	Mandatory	Age in days when the diagnosis was made for the disease phase.	ncit:C168972	_undefined_	_undefined_	_undefined_
VD	YEAR_AT_DISEASE_PHASE	Number	Mandatory	Year when the diagnosis was made for the disease phase.	ncit:C168823	_undefined_	_undefined_	_undefined_


DD	Protocol
TD	Course Timing
TG	One row per subject per course(s)
VD	COURSE	Code	Mandatory	The type of protocol treatment course administered.	ncit:C168807	_undefined_	_undefined_	_undefined_
PD						Prephase	A chemotherapy treatment administered prior to the definitive chemotherapy treatment.	ncit:C168826
PD						Induction	The first choice of treatment for a particular type of cancer.	ncit:C158876
PD						Intensification	A second round of intense chemotherapy as part of consolidation therapy.	ncit:C173105
PD						Consolidation	Treatment that is given after initial therapy to kill any remaining cancer cells.	ncit:C15679
PD						Stem Cell Transplant Conditioning	A regimen that can be used as a conditioning regimen for hematopoietic stem cell transplantation (HSCT).	ncit:C168794
PD						Maintenance	Continuation of treatment for an extended period of time to prevent relapse.	ncit:C15688
PD						Interim Maintenance	A less intense phase of chemotherapy in between each course of delayed intensification.	ncit:C178069
PD						Delayed Intensification	A repeat of the first two months of induction and consolidation chemotherapy in high-risk and very-high-risk ALL protocols with the goal of eliminating residual drug-resistant cells	ncit:C178270
PD						Continuation	A period in a clinical study during which subjects receive continuation therapy. This therapy is usually different from the therapy given during the induction phase and administered over a longer period of time.	ncit:C123452
PD						Investigational Agent	A new drug or biological drug that is used in a clinical investigation. The term also includes a biological product that is used in vitro for diagnostic purposes.	ncit:C49135
VD	COURSE_NUMBER	Number	Mandatory	The number assigned to a course of therapeutic agent administration, indicating where a particular course of treatment falls within a sequence of treatments.	ncit:C166235	_undefined_	_undefined_	_undefined_
VD	AGE_AT_COURSE_START	Number	Mandatory	Age of subject (in days) at the start of the course.	ncit:C168850	_undefined_	_undefined_	_undefined_
VD	AGE_AT_COURSE_END	Number	Mandatory	Age of subject (in days) at the end of the course.	ncit:C168851	_undefined_	_undefined_	_undefined_


DD	Protocol
TD	Off Protocol Therapy/Study
TG	One row per subject per off protocol therapy or off study per reason off
VD	AGE_OFF	Number	Mandatory	Age in Days When Off Protocol Therapy or Study		_undefined_	_undefined_	_undefined_
VD	DISEASE_PHASE	Code	Mandatory	The stage or period of an individual's disease.	ncit:C168878	_undefined_	_undefined_	_undefined_	Note: Disease phase could be "Initial Diagnosis" phase, a "Relapse" phase, or a "Progression" phase.
PD						Initial Diagnosis	The first diagnosis of the individual's condition.	ncit:C156813
PD						Relapse	The return of a disease after a period of remission.	ncit:C38155
PD						Refractory	Not responding to treatment.	ncit:C38014
VD	DISEASE_PHASE_NUMBER	Number	Mandatory	The number of the disease phase.	ncit:C173258	_undefined_	_undefined_	_undefined_
VD	COURSE	Code	Mandatory	The type of protocol treatment course administered.	ncit:C168807	_undefined_	_undefined_	_undefined_
PD						Prephase	A chemotherapy treatment administered prior to the definitive chemotherapy treatment.	ncit:C168826
PD						Induction	The first choice of treatment for a particular type of cancer.	ncit:C158876
PD						Intensification	A second round of intense chemotherapy as part of consolidation therapy.	ncit:C173105
PD						Consolidation	Treatment that is given after initial therapy to kill any remaining cancer cells.	ncit:C158876
PD						Stem Cell Transplant Conditioning	A regimen that can be used as a conditioning regimen for hematopoietic stem cell transplantation (HSCT).	ncit:C168794
PD						Maintenance	Continuation of treatment for an extended period of time to prevent relapse.	ncit:C15688
PD						Interim Maintenance	A less intense phase of chemotherapy in between each course of delayed intensification.	ncit:C178069
PD						Delayed Intensification	A repeat of the first two months of induction and consolidation chemotherapy in high-risk and very-high-risk ALL protocols with the goal of eliminating residual drug-resistant cells	ncit:C178270
PD						Continuation	A period in a clinical study during which subjects receive continuation therapy. This therapy is usually different from the therapy given during the induction phase and administered over a longer period of time.	ncit:C123452
PD						Investigational Agent	A new drug or biological drug that is used in a clinical investigation. The term also includes a biological product that is used in vitro for diagnostic purposes.	ncit:C49135
VD	COURSE_NUMBER	Number	Mandatory	The number assigned to a course of therapeutic agent administration, indicating where a particular course of treatment falls within a sequence of treatments.	ncit:C166235	_undefined_	_undefined_	_undefined_
VD	OFF_TYPE	Code	Mandatory	The code used to designate that the subject went off therapy or off the study.	ncit:C173256	_undefined_	_undefined_	_undefined_
PD						Protocol Therapy	No longer receiving protocol therapy.	ncit:C173257
PD						Study	No longer participating in a study; not being followed and will not be retreated.	ncit:C29851
VD	REASON_OFF	Code	Mandatory	A coded value specifying why the subject is removed from a study.	ncit:C93611	_undefined_	_undefined_	_undefined_	Note: If multiple reasons off, include one observation per reason off.
PD						Death	Specifies whether the life of an entity has ceased.	ncit:C93546
PD						Lost to Follow-Up	The subject was not available for follow-up procedures.	ncit:C70740
PD						Completion of Follow-Up	The follow-up protocols were completed.	ncit:C178071
PD						Completion of Planned Therapy	The end of the planned treatment.	ncit:C168935
PD						Physician Decision	A position, opinion or judgment reached after consideration by a physician with reference to subject.	ncit:C48250
PD						Ineligible	The state or quality of being disqualified by law, rule, or provision.	ncit:C40412
PD						Withdrawal of Consent	When the permission to do something is rescinded or withdrawn.	ncit:C48271
PD						Subject/Guardian Refused Further tTeatment	The subject or their guardian has refused further treatment.	ncit:C168934
PD						Subject Non-Compliance	Failure of a patient to follow medical advice, take medication as directed, or adhere to a prescribed course of treatment.	ncit:C91752
PD						Failure to Attain Remission	Remission status was not attained.	ncit:C178072
PD						Relapse	The return of a disease after a period of remission.	ncit:C38155
PD						Adverse Event	Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).	ncit:C41331
PD						Secondary Malignancy Neoplasm	A malignant neoplasm that arises from a pre-existing lower grade lesion, or as a result of a primary lesion that has spread to secondary sites, or due to a complication of a cancer treatment.	ncit:C4968
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	ANOTHER_STUDY	Code	Mandatory	The subject was enrolled in another therapeutic study after the off protocol study.	ncit:C178073	_undefined_	_undefined_	_undefined_
PD						No	The non-affirmative response to a question.	ncit:C49487
PD						Yes	The affirmative response to a question.	ncit:C49488
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234


DD	Demographics
TD	Demographics
TG	One row per subject
VD	SEX	Code	Mandatory	The assemblage of physical properties or qualities by which male is distinguished from female; the physical difference between male and female; the distinguishing peculiarity of male or female.	ncit:C28421	_undefined_	_undefined_	_undefined_
PD						Male	A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both.	ncit:C20197
PD						Female	A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both.	ncit:C16576
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	RACE	Code	Mandatory	An arbitrary classification of a taxonomic group that is a division of a species. It usually arises as a consequence of geographical isolation within a species and is characterized by shared heredity, physical attributes and behavior, and in the case of humans, by common history, nationality, or geographic distribution.	ncit:C17049	_undefined_	_undefined_	_undefined_
PD						American Indian or Alaska Native	A person having origins in any of the original peoples of North and South America (including Central America) and who maintains tribal affiliation or community attachment. (OMB)	ncit:C41259
PD						Asian	A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent, including for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. (OMB)	ncit:C41260
PD						Black or African American	A person having origins in any of the Black racial groups of Africa. Terms such as "Haitian" or "Negro" can be used in addition to "Black or African American". (OMB)	ncit:C16352
PD						Multiracial	Having ancestors of several or various races.	ncit:C67109
PD						Native Hawaiian or Other Pacific Islander	A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. (OMB)	ncit:C41219
PD						White	A person having origins in any of the original peoples of Europe, the Middle East, or North Africa. (OMB)	ncit:C41261
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	ETHNICITY	Code	Mandatory	A social group characterized by a distinctive social and cultural tradition that is maintained from generation to generation. Members share a common history and origin and a sense of identification with the group. They have similar and distinctive features in their lifestyle habits and shared experiences. They often have a common genetic heritage which may be reflected in their experience of health and disease.	ncit:C16564	_undefined_	_undefined_	_undefined_
PD						Hispanic or Latino	A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. The term, "Spanish origin," can be used in addition to "Hispanic or Latino." (OMB)	ncit:C17459
PD						Not Hispanic or Latino	A person not of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race.	ncit:C41222
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234


DD	Demographics
TD	Medical History
TG	One row per subject per prior medical history
VD	MEDICAL_HISTORY	Code	Mandatory	Medical History		_undefined_	_undefined_	_undefined_
PD						Trisomy 21	A chromosomal abnormality consisting of the presence of a third copy of chromosome 21 in somatic cells.	ncit:C43224
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Determination of a value is not relevant in the current context.	ncit:C48660


DD	Demographics
TD	Survival Characteristics
TG	One row per subject per cause of death, per treatment type, per cause of death detail
VD	AGE_AT_LKSS	Number	Mandatory	Age of subject (in days) at the last known survival status.	ncit:C168844	_undefined_	_undefined_	_undefined_
VD	LKSS	Code	Mandatory	The individual's last known survival status.	ncit:C168931	_undefined_	_undefined_	_undefined_
PD						Alive	Showing characteristics of life; displaying signs of life.	ncit:C37987
PD						Dead	The cessation of life.	ncit:C28554
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
VD	LKSS_WITH_DISEASE	Code	Mandatory	The last known survival status of the individual with the disease.	ncit:C178074	_undefined_	_undefined_	_undefined_
PD						No	The non-affirmative response to a question.	ncit:C49487
PD						Yes	The affirmative response to a question.	ncit:C49488
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	AGE_LOST_TO_FOLLOW_UP	Number	Mandatory	Age of subject (in days) when the subject was lost to follow-up.	ncit:C172679	_undefined_	_undefined_	_undefined_
VD	CAUSE_OF_DEATH	Code	Mandatory	The circumstance or condition that results in the death of a living being.	ncit:C81239	_undefined_	_undefined_	_undefined_	Note: If multiple causes of death, include one observation per cause of death.
PD						Disease Progression	An indication that the subject has died due to the progression of their disease.	ncit:C168970
PD						Treatment-Related Mortality	A death that is considered to be causally linked to a treatment.	ncit:C166165
PD						Secondary Malignancy	A malignant neoplasm that arises from a pre-existing lower grade lesion, or as a result of a primary lesion that has spread to secondary sites, or due to a complication of a cancer treatment.	ncit:C4968
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	TRM_TYPE	Code	Mandatory	The type of treatment related to the mortality of the subject.	ncit:C173260	_undefined_	_undefined_	_undefined_	Note: If multiple treatment types, include one observation per treatment type.
PD						Stem Cell Transplant	A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.	ncit:C15431
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	CAUSE_OF_DEATH_DETAIL	Code	Optional	Specific details of the cause of death.	ncit:C168868	_undefined_	_undefined_	_undefined_	Note: If multiple cause of death details, include one observation per cause of death detail.
PD						Hemorrhage	In medicine, loss of blood from damaged blood vessels. A hemorrhage may be internal or external, and usually involves a lot of bleeding in a short time.	ncit:C26791
PD						Bacterial Infection	An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.	ncit:C2890
PD						Viral Infection	Any disease caused by a virus.	ncit:C3439
PD						Fungal Infection	An infection caused by a fungus.	ncit:C3245
PD						Infection	The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.	ncit:C128320
PD						Immunotherapy-Related	An observation that a situation is related to immunotherapy received.	ncit:C168874
PD						Sinusoidal Obstruction Syndrome	A disorder characterized by inflammation and damage of the hepatic sinusoidal endothelial cells of the hepatic venules that leads to venular occlusion and hepatocellular necrosis. It is most often a conditioning-related toxicity that results as a complication of hematopoietic stem cell transplantation (HSCT). It has also been described in populations of individuals who have ingested pyrrolizidine plant alkaloids. The clinical signs and symptoms include hyperbilirubinemia, hepatomegaly, and fluid retention.	ncit:C26793
PD						Multi-Organ Failure	Complete impairment of two or more organs or organ systems.	ncit:C75568
PD						Acute Respiratory Distress Syndrome	Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.	ncit:C3353
PD						Graft Versus Host Disease	A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.	ncit:C3063
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	CAUSE_OF_DEATH_RANKING	Code	Mandatory	Assigning a weighted relevance to the cause of death.	ncit:C168932	_undefined_	_undefined_	_undefined_	Note: Contributory refers to additional cause of death, not necessarily the ordinal ranking of causes of death. There may be multiple secondary causes of death.
PD						Primary	The first significant event which ultimately led to death.	ncit:C99531
PD						Contributory	Any factor contributing to the cause of death.	ncit:C168948
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234


DD	Disease Attributes
TD	Disease Characteristics
TG	One row per subject per disease phase per disease site
VD	DISEASE_PHASE	Code	Mandatory	The stage or period of an individual's disease.	ncit:C168878	_undefined_	_undefined_	_undefined_
PD						Initial Diagnosis	The first diagnosis of the individual's condition.	ncit:C156813
PD						Relapse	The return of a disease after a period of remission.	ncit:C38155
PD						Refractory	Not responding to treatment.	ncit:C38014
VD	DISEASE_PHASE_NUMBER	Number	Mandatory	The number of the disease phase.	ncit:C173258	_undefined_	_undefined_	_undefined_
VD	ALL_TYPE	Code	Mandatory	Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.	ncit:C3167	_undefined_	_undefined_	_undefined_
PD						B-ALL	The most frequent type of acute lymphoblastic leukemia. Approximately 75% of cases occur in children under six years of age. This is a good prognosis leukemia. In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%. Approximately 80% of children appear to be cured. In the adult age group the complete remission rate is 60-85%. (WHO, 2001)	ncit:C8644
PD						T-ALL	Acute lymphoblastic leukemia of T-cell origin. It comprises about 15% of childhood cases and 25% of adult cases. It is more common in males than females. (WHO, 2001)	ncit:C3183
PD						Acute Leukemia, ambiguous lineage (mixed or biphenotypic)	An acute leukemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells. (WHO, 2001)	ncit:C7464
PD						Mixed Phenotype Acute Leukemia	An acute leukemia of ambiguous lineage. It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.	ncit:C82179
VD	DISEASE_SITE	Code	Mandatory	The anatomic site of the disease.	ncit:C173263	_undefined_	_undefined_	_undefined_	Note: If multiple sites of disease involvement, include one observation per site.
PD						Bone Marrow	The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.	ncit:C12431
PD						Central Nervous System	The part of the nervous system that consists of the brain, spinal cord, and meninges.	ncit:C12438
PD						Testes	Either of the paired male reproductive glands that produce the male germ cells and the male hormones.	ncit:C12412
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	CNS_DISEASE_STATUS	Code	Mandatory	The status of central nervous system leukemia at the time of diagnosis.	ncit:C116832	_undefined_	_undefined_	_undefined_
PD						CNS1	The status of central nervous system leukemia at diagnosis, where there is an absence of blasts on a cerebral spinal fluid cytospin preparation, regardless of the number of white blood cells.	ncit:C116833
PD						CNS2	The status of central nervous system leukemia at diagnosis, where there are less than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts; or greater than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is considered negative by Steinherz/Bleyer algorithm.	ncit:C116834
PD						CNS3	The status of central nervous system leukemia at diagnosis, where there are more than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts; with or without clinical signs of CNS leukemia.	ncit:C116835
PD						CNS2a	The status of central nervous system leukemia at diagnosis, where there are less than 10 red blood cells and less than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts.	ncit:C116836
PD						CNS2b	The status of central nervous system leukemia at diagnosis, where there are 10 or more red blood cells and less than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts.	ncit:C116837
PD						CNS2c	The status of central nervous system leukemia at diagnosis, where there are 10 or more red blood cells and 5 or more white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts and is considered negative by Steinherz/Bleyer algorithm.	ncit:C116838
PD						CNS3a	The status of central nervous system leukemia at diagnosis, where there are less than 10 red blood cells and 5 or more white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts.	ncit:C116840
PD						CNS3b	The status of central nervous system leukemia at diagnosis, where there are 10 or more red blood cells and 5 or more white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is considered positive by Steinherz/Bleyer algorithm.	ncit:C116841
PD						CNS3c	The status of central nervous system leukemia at diagnosis, where there are clinical signs of central system leukemia (such as facial nerve palsy, brain/eye involvement, or hypothalamic syndrome).	ncit:C116843
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	BULK_MED_MASS	Code	Optional	When the maximum width of a mass is equal or greater than one-third of the internal transverse diameter of the thorax at the level of T5/6 on a PA CXR. Bulk at an alternate site is defined as any mass measuring 10 cm or more by any imaging study.	ncit:C178075	_undefined_	_undefined_	_undefined_
PD						No	The non-affirmative response to a question.	ncit:C49487
PD						Yes	The affirmative response to a question.	ncit:C49488
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	PRIOR_STEROIDS_WEEK	Code	Mandatory	The subject received steroids within one week prior to diagnosis of the disease phase.	ncit:C178076	_undefined_	_undefined_	_undefined_
PD						No	The non-affirmative response to a question.	ncit:C49487
PD						Yes	The affirmative response to a question.	ncit:C49488
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	PRIOR_STEROIDS_MONTH	Code	Mandatory	The subject received steroids within one month prior to diagnosis of the disease phase.	ncit:C178077	_undefined_	_undefined_	_undefined_
PD						No	The non-affirmative response to a question.	ncit:C49487
PD						Yes	The affirmative response to a question.	ncit:C49488
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234


DD	Testing
TD	Vitals
TG	One row per subject per vitals sign record
VD	AGE_AT_VITALS	Number	Optional	Vital signs (such as height, weight, and blood pressure) directly measure an individual's current state of attributes.	ncit:C154628	_undefined_	_undefined_	_undefined_
VD	DISEASE_PHASE	Code	Optional	The stage or period of an individual's disease.	ncit:C168878	_undefined_	_undefined_	_undefined_	Note: Disease phase could be "Initial Diagnosis" phase, a "Relapse" phase, or a "Progression" phase.
PD						Initial Diagnosis	The first diagnosis of the individual's condition.	ncit:C156813
PD						Relapse	The return of a disease after a period of remission.	ncit:C38155
PD						Refractory	Not responding to treatment.	ncit:C38014
VD	DISEASE_PHASE_NUMBER	Number	Optional	The number of the disease phase.	ncit:C173258	_undefined_	_undefined_	_undefined_
VD	COURSE	Code	Optional	The type of protocol treatment course administered.	ncit:C168807	_undefined_	_undefined_	_undefined_
PD						Prephase	A chemotherapy treatment administered prior to the definitive chemotherapy treatment.	ncit:C168826
PD						Induction	The first choice of treatment for a particular type of cancer.	ncit:C158876
PD						Intensification	A second round of intense chemotherapy as part of consolidation therapy.	ncit:C173105
PD						Consolidation	Treatment that is given after initial therapy to kill any remaining cancer cells.	ncit:C158876
PD						Stem Cell Transplant Conditioning	A regimen that can be used as a conditioning regimen for hematopoietic stem cell transplantation (HSCT).	ncit:C168794
PD						Maintenance	Continuation of treatment for an extended period of time to prevent relapse.	ncit:C15688
PD						Interim Maintenance	A less intense phase of chemotherapy in between each course of delayed intensification.	ncit:C178069
PD						Delayed Intensification	A repeat of the first two months of induction and consolidation chemotherapy in high-risk and very-high-risk ALL protocols with the goal of eliminating residual drug-resistant cells	ncit:C178270
PD						Continuation	A period in a clinical study during which subjects receive continuation therapy. This therapy is usually different from the therapy given during the induction phase and administered over a longer period of time.	ncit:C123452
PD						Investigational Agent	A new drug or biological drug that is used in a clinical investigation. The term also includes a biological product that is used in vitro for diagnostic purposes.	ncit:C49135
VD	COURSE_NUMBER	Number	Optional	The number assigned to a course of therapeutic agent administration, indicating where a particular course of treatment falls within a sequence of treatments.	ncit:C166235	_undefined_	_undefined_	_undefined_
VD	VITALS_TEST	Code	Optional	The act of assessing an individual's current temperature, heart rate, respiratory rate, pulse oxygenation, and blood pressure.	ncit:C49672	_undefined_	_undefined_	_undefined_
PD						Weight	The weight of a subject.	ncit:C81328
PD						Height	The vertical measurement or distance from the base to the top of a subject or participant.	ncit:C164634
VD	VITALS_RESULT	String	Optional	The outcome of the vital signs assessment.	ncit:C83108	_undefined_	_undefined_	_undefined_
VD	VITALS_RESULT_NUMERIC	Number	Optional	The numeric values of the vital signs.	ncit:C173268	_undefined_	_undefined_	_undefined_
VD	VITALS_RESULT_UNIT	Code	Optional	The unit used to record and describe the result of a test investigating a vital sign.	ncit:C49675	_undefined_	_undefined_	_undefined_
PD						kg	A basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds.	ncit:C28252
PD						cm	A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch	ncit:C49668
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234


DD	Testing
TD	Labs
TG	One row per subject per lab value
VD	AGE_AT_LAB	Number	Mandatory	Age of subject (in days) when the laboratory test was performed.	ncit:C172691	_undefined_	_undefined_	_undefined_
VD	LAB_CATEGORY	Code	Mandatory	A classification of the laboratory test.	ncit:C83017	_undefined_	_undefined_	_undefined_
PD						Peripheral Blood Analysis	A laboratory analysis of a sample of peripheral blood.	ncit:C173271
PD						Cerebrospinal Fluid Analysis	A laboratory analysis of a sample of cerebrospinal fluid.	ncit:C173272
PD						Bone Marrow Analysis	A laboratory analysis of a sample of bone marrow.	ncit:C173273
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	LAB_TEST	Code	Mandatory	A character or string that represents the full name of the laboratory assessment.	ncit:C117142	_undefined_	_undefined_	_undefined_
PD						Platelets	The determination of the number of platelets in a biospecimen.	ncit:C51951
PD						RBC	The determination of the number of erythrocytes in a biospecimen.	ncit:C51946
PD						WBC	A test to determine the number of leukocytes in a biospecimen.	ncit:C51948
PD						Absolute Neutrophil Count	The real number of white blood cells (WBC) that are neutrophils. It is derived by multiplying the WBC count by the percent of neutrophils in the differential WBC count. The normal range for ANC is 1.5 to 8.0 (1,500 to 8,000/mm3).	ncit:C63321
PD						Blasts	The determination of the number of blast cells present in a blood sample.	ncit:C74605
PD						Hemoglobin	A quantitative measurement of the amount of hemoglobin present in a sample.	ncit:C64848
VD	LAB_SPEC_TYPE	Code	Mandatory	The type of a material sample taken from a biological entity for laboratory testing.	ncit:C83315	_undefined_	_undefined_	_undefined_
PD						Blood	A small volume of blood removed for testing or storage.	ncit:C17610
PD						Cerebrospinal Fluid	A specimen of cerebrospinal fluid.	ncit:C185194
PD						Bone Marrow	A biological sample containing components collected from bone marrow of an experimental subject.	ncit:C164009
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	LAB_RESULT	String	Mandatory	The outcome of a laboratory test.	ncit:C36292	_undefined_	_undefined_	_undefined_
VD	LAB_RESULT_NUMERIC	Number	Mandatory	A numeric representation of a test result.	ncit:C70952	_undefined_	_undefined_	_undefined_
VD	LAB_RESULT_UNIT	Code	Mandatory	The numeric unit that expresses the lab result.	ncit:C173274	_undefined_	_undefined_	_undefined_
PD						%	A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).	ncit:C48570
PD						count/mm3	A count of items per cubic millimeter of sample.	ncit:C173275
PD						g/dL	A unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one deciliter (100 milliliters). The concept also refers to the metric unit of mass density (volumic mass) defined as the density of substance which mass equal to one gram occupies the volume one deciliter.	ncit:C64783
PD						U/L	An arbitrary unit of substance concentration equal to the concentration at which one liter of mixture contains one unit of a substance.	ncit:C67456
PD						mm/h	A unit of both speed (scalar) and velocity (vector), defined as the distance of one millimeter travelled per unit time equal to one hour.	ncit:C67419
PD						mg/L	A metric unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one cubic meter. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one gram occupies the volume of one cubic meter.	ncit:C64572
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	LAB_METHOD	Code	Mandatory	A systematic course of action that is performed in order to complete a laboratory test.	ncit:C83312	_undefined_	_undefined_	_undefined_
PD						Flow Cytometry	A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.	ncit:C16585
PD						Morphology	The science of the form and structure of organisms (plants, animals, and other forms of life), or of their parts, and the study or science of the same. In pathology, the specific appearance of cells and tissues (normal and abnormal) under the light or electron microscope.	ncit:C17943
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	BM_MORPHOLOGY	Code	Mandatory	The morphology characteristics of the bone marrow blasts.	ncit:C178079	_undefined_	_undefined_	_undefined_
PD						M1 (less than 5% blasts)	A semi-quantitative microscopic finding indicating that 5 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells.	ncit:C137698
PD						M2 (5-25% blasts)	A semi-quantitative microscopic finding indicating that between 5 and 25 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	ncit:C146709
PD						M3 (greater than 25% blasts)	A semi-quantitative microscopic finding indicating that 25 percent or more of the nucleated cells in a bone marrow sample are immature mononuclear cells.	ncit:C140330
VD	TRAUMATIC_TAP	Code	Mandatory	Contamination of a cerebrospinal fluid sample by red blood cells greater than 10/mm3.	ncit:C168879	_undefined_	_undefined_	_undefined_	Notes: Traumatic tap is defined as cerebrospinal fluid with greater than 10 RBC/mm3.
PD						No	The non-affirmative response to a question.	ncit:C49487
PD						Yes	The affirmative response to a question.	ncit:C49488
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234


DD	Testing
TD	Molecular Analysis
TG	One row per subject per molecular analysis modality (per molecular abnormality)
VD	AGE_AT_MOLECULAR_ANALYSIS	Number	Mandatory	Age of subject (in days) when molecular analysis was performed.	ncit:C168848	_undefined_	_undefined_	_undefined_
VD	MOLECULAR_ANALYSIS_METHOD	Code	Mandatory	Molecular Analysis Method	ncit:C158954	_undefined_	_undefined_	_undefined_
PD						Karyotype	The assessment of the chromosomal morphology and number in somatic cells of an individual.	ncit:C25215
PD						Fluorescence In Situ Hybridization	A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping.	ncit:C17563
PD						Reverse Transcriptase-Polymerase Chain Reaction	A laboratory procedure in which an RNA strand is first transcribed into a DNA complement and then subjected to PCR amplification. Transcribing an RNA strand into a DNA complement is termed reverse transcription and is done by the enzyme reverse transcriptase.	ncit:C18136
PD						Next Generation Sequencing	Technologies that facilitate the rapid determination of the DNA sequence of large numbers of strands or segments of DNA.	ncit:C101293
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	MOLECULAR_ANALYSIS_SAMPLE_SOURCE	Code	Mandatory	The anatomic source of the molecular analysis sample.	ncit:C178080	_undefined_	_undefined_	_undefined_
PD						Blood	A small volume of blood removed for testing or storage.	ncit:C17610
PD						Bone Marrow	A biological sample containing components collected from bone marrow of an experimental subject.	ncit:C164009
VD	KARYOTYPE_STATUS	Code	Mandatory	The status of the subject's karyotype.	ncit:C168871	_undefined_	_undefined_	_undefined_
PD						Normal Karyotype	The assessment of the karyotype is that it is normal.	ncit:C173277
PD						Abnormal Karyotype	Any abnormality in the number, length, centromere position, banding pattern or differences between the sex chromosomes that is not representative of a normal set of chromosomes.	ncit:C168875
VD	ISCN	String	Mandatory	A karyotype finding as classified by the International System for Human Cytogenetic Nomenclature.	ncit:C173278	_undefined_	_undefined_	_undefined_
VD	NUM_CHROMOSOMES	Number	Mandatory	The number of chromosomes upon karyotype analysis.	ncit:C177370	_undefined_	_undefined_	_undefined_
VD	MOLECULAR_ABNORMALITY	Code	Mandatory	A molecular or cytogenic abnormality which occurs in either human disease states or disease models.	ncit:C3910	_undefined_	_undefined_	_undefined_	Note: If multiple molecular abnormalities, include one observation per molecular abnormality.
PD						t(9;22)	A translocation between chromosome 9 and chromosome 22 that may be associated with Philadelphia chromosome and increased susceptibility to several types of leukemia.	ncit:C117116
PD						t(1;19)	A cytogenetic abnormality that involves a translocation between chromosomes 1 and 19.	ncit:C128654
PD						t(12;21)(p13;q22)	A translocation between chromosomes 12 and 21 involved in TEL-AML1 oncogene formation. The translocation produces a chimeric gene encoding a protein consisting of the N-terminal HLH domain of the TEL ETS-like transcription factor fused with a nearly complete AML1 protein. t(12;21) is the most frequent translocation causing ALL, accounting for 20% of ALL cases.	ncit:C13727
PD						t(4;11)(q21;q23)	A chromosomal abnormality consisting of the translocation of 4q21 with 11q23.	ncit:C36365
PD						MLL Rearrangement (Translocation)	A cytogenetic abnormality that refers to any translocation involving the MLL (KMT2A) gene.	ncit:C167144
PD						t(8;14)(q24;q32)	A chromosomal translocation that fuses 8q24 with 14q32. This juxtaposes the MYC gene with the promoter regions of the immunoglobulin heavy chain gene locus, which results in overexpression of Myc proto-oncogene protein in B-cells bearing the translocation.	ncit:C36319
PD						Trisomy 10	A chromosomal abnormality consisting of the presence of a third copy of chromosome 10 in somatic cells.	ncit:C81729
PD						Trisomy 17	A chromosomal abnormality consisting of the presence of a third copy of chromosome 17 in somatic cells.	ncit:C37865
PD						Trisomy 4	A chromosomal abnormality consisting of the presence of a third copy of chromosome 4 in somatic cells.	ncit:C36530
PD						iAMP21	A cytogenetic abnormality that refers to the allelic gain of an internal part of chromosome 21. It is a rare high-risk chromosomal abnormality that occurs in approximately 2-5% of pediatric patients with B-cell precursor Acute Lymphoblastic Leukemia. This abnormality has been associated with a poor outcome in patients treated by standard protocols.	ncit:C124874
VD	CHROMOSOME	String	Mandatory	One of the bodies in the cell nucleus that is the bearer of genes, has the form of a delicate chromatin filament during interphase, contracts to form a compact cylinder segmented into two arms by the centromere during metaphase and anaphase stages of cell division, and is capable of reproducing its physical and chemical structure through successive cell divisions.	ncit:C13202	_undefined_	_undefined_	_undefined_
VD	GENE1	String	Mandatory	The gene symbol that represents either a single gene that has a mutation or the gene that comprises the 5' portion of the coding sequence involved in a fusion gene mutation.	ncit:C173595	_undefined_	_undefined_	_undefined_
VD	GENE2	String	Mandatory	The gene symbol that represents the gene that comprises the 3' portion of the coding sequence for a fusion gene	ncit:C171253	_undefined_	_undefined_	_undefined_
VD	VARIANT_TYPE	Code	Mandatory	A variation in or modification of the molecular sequence of a gene or gene product.	ncit:C97926	_undefined_	_undefined_	_undefined_
PD						Translocation	A genetic exchange where a piece of one chromosome is transfered to another chromosome.	ncit:C3420
PD						Inversion	A structural change in genomic DNA where the 5' to 3' order of a nucleotide sequence is completely reversed to the 3' to 5' order relative to its adjacent sequences. This inversion is termed either pericentric, if it includes the centromere of a chromosome, or pancentric, if it excludes the centromere. An inversion mutation abnormality may be heritable or occur somatically.	ncit:C45589
PD						Mutation	Any transmissible change in the genetic material of an organism, which can result from radiation, viral infection, transposition, treatment with mutagenic chemicals and errors during DNA replication or meiosis. The effects of mutation range from single base changes to loss or gain of complete chromosomes. As many of the simpler alterations to DNA may be repaired, such changes are only heritable once the change is fixed in the DNA by the process of replication. Mutations may be associated with genetic diversity or with pathologies including cancer.	ncit:C45576
PD						Single Nucleotide Variant	A variation of a single nucleotide at a specific location of the genome due to base substitution, which is found at any frequency in the population.	ncit:C164674
PD						Copy Number Alteration	Variation in the number of copies of a particular sequence within the genetic material of an individual. Large-scale copy number polymorphisms are common and widely distributed in the human genome.	ncit:C40207
PD						Rearrangement	Any process affecting a DNA sequence that results in the gain, loss or exchange of DNA between chromosomes and/or autonomous replicons.	ncit:C21069
PD						Deletion	Any rearrangement to the genomic content that results in the loss of one or more nucleotides of DNA. Deletions are generally irreversible rearrangements. They may alter the reading frame of a gene, or may result in loss of large chromosomal regions.	ncit:C19296
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	GENETIC_SEQ	String	Mandatory	A variation in the nucleic acid sequence of a specific gene.	ncit:C97927	_undefined_	_undefined_	_undefined_
VD	AA_MUTATION	String	Mandatory	A variation in the sequence of a specific gene product.	ncit:C97928	_undefined_	_undefined_	_undefined_
VD	MOLECULAR_ABNORMALITY_RESULT	Code	Mandatory	An indicator for whether a molecular analysis procedure was performed and whether the assay detected a molecular abnormality.	ncit:C173596	_undefined_	_undefined_	_undefined_	Note: This variable indicates the result of testing for the molecular abnormality listed in MOLECULAR_ABNORMALITY
PD						Positive	A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.	ncit:C38758
PD						Negative	A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.	ncit:C38757
PD						Not Done	Indicates a task, process or examination that has either not been initiated or not been completed.	ncit:C49484
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	DNA_INDEX_NUMERIC	Number	Mandatory	The ratio of the DNA content or chromosome number in a tumor sample compared to that in a normal sample.	ncit:C86972	_undefined_	_undefined_	_undefined_
VD	TRANSLOCATION_STATUS	Code	Mandatory	The finding of the chromosomal translocation analysis.	ncit:C63326	_undefined_	_undefined_	_undefined_
PD						Balanced	Interchanges of genetic material among different chromosomes following the breaking off of pieces of chromosomes such that the total chromosome composition may still contain all of the genetic material.Balanced Chromosomal Rearrangement.	ncit:C6822
PD						Unbalanced	Interchanges of genetic material among different chromosomes following the breaking off of pieces of chromosomes such that the total chromosome composition does not contain all of the genetic material.	ncit:C6823
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234


DD	Treatment
TD	Radiation Therapy
TG	One row per subject per radiation therapy administration
VD	AGE_AT_RT_START	Number	Mandatory	Age of subject (in days) at the start of radiation therapy.	ncit:C172695	_undefined_	_undefined_	_undefined_
VD	AGE_AT_RT_END	Number	Mandatory	Age of subject (in days) at the end of radiation therapy.	ncit:C172696	_undefined_	_undefined_	_undefined_
VD	RT_SITE	Code	Mandatory	The anatomic site of the radiation therapy.	ncit:C173281	_undefined_	_undefined_	_undefined_
PD						Cranium	The bones that form the head, made up of the bones of the braincase and face.	ncit:C12789
PD						Testes	Either of the paired male reproductive glands that produce the male germ cells and the male hormones.	ncit:C12412
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234


DD	Treatment
TD	Stem Cell Transplant
TG	One row per subject per stem cell transplant
VD	AGE_AT_SCT	Number	Optional	Age of subject (in days) at the time of stem-cell transplantation.	ncit:C168853	_undefined_	_undefined_	_undefined_
VD	SCT_TYPE	Code	Optional	Stem Cell Transplantion Type	ncit:C168864	_undefined_	_undefined_	_undefined_
PD						Autologous	Stem cell transfer or transplantation in which the patient is his own donor.	ncit:C16039
PD						Allogeneic	A clinical treatment in which hematopoietic stem cells (HSCs) are transferred from one genetically dissimilar individual to another.	ncit:C46089
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	SCT_SOURCE	Code	Optional	Stem Cell Transplantion Type	ncit:C168864	_undefined_	_undefined_	_undefined_
PD						Bone Marrow	The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.	ncit:C12431
PD						Peripheral Blood	Blood drawn from a limb.	ncit:C173496
PD						Cord Blood	Blood present in the umbilical vessels at the time of delivery. If cryopreserved at birth, cord blood can serve as a source of hematopoietic progenitor cells for transplantation to a patient later diagnosed and treated for a hematopoietic disorder.	ncit:C13300
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	SCT_DONOR_RELATIONSHIP	Code	Optional	Stem Cell Transplant Donor Relationship	ncit:C168870	_undefined_	_undefined_	_undefined_
PD						Biological Sibling	A person's brother or sister with whom they share a genetic makeup inherited from one or both of their shared biological parents.	ncit:C100809
PD						Biological Parent	The male who supplied the sperm or the female who supplied the egg which resulted in one's conception.	ncit:C166114
PD						Biological Relative	A person related by descent rather than by marriage or law.	ncit:C71384
PD						Biologically Unrelated	A person who is biologically unrelated to another individual.	ncit:C130053
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	HLA_MATCH	Code	Optional	A process in which blood or tissue samples are analyzed to determine their human leukocyte antigen (HLA) profiles so that transplant materials can be transferred into a patient with the same or similar profile.	ncit:C169009	_undefined_	_undefined_	_undefined_
PD						Match	The state when a recipient and their donor have the same alleles for tissue markers. A full match includes HLA-A, HLA-B, HLA-C, and HLA-DRB1. HLA match typing may also include alleles in the HLA-DQ serogroup.	ncit:C129972
PD						Non-Match	The state when a recipient of a hematopoietic stem cell transplant is not fully matched with their donor for HLA-A, HLA-B, HLA-C, and HLA-DRB1.	ncit:C126298
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	NUMBER_HLA	Number	Optional	The number of human leukocyte antigens that were evaluated.	ncit:C173301	_undefined_	_undefined_	_undefined_
VD	NUMBER_MATCHES	Number	Optional	The number of human leukocyte antigens that matched between the donor and the recipient.	ncit:C173302	_undefined_	_undefined_	_undefined_
VD	SCT_CONDITIONING_TYPE	Code	Optional	Type of conditioning the subject received prior to stem-cell transplantation.	ncit:C169014	_undefined_	_undefined_	_undefined_
PD						Myeloablative	A conditioning regimen with high doses of chemotherapy or radiation to eliminate host hematopoietic stem cells prior to restitution via transplantation.	ncit:C131679
PD						Reduced Intensity Conditioning/Reduced Toxicity Conditioning	A method of preparation for stem cell transplant that uses less than standard doses of chemotherapy and radiation prior to the transfer of stem cells, with the goal of providing protection against graft vs. host disease, while simultaneously minimizing the toxic effects of the conditioning treatment.	ncit:C116471
PD						Non-Myeloablative	A modification of the standard method of allogeneic hematopoietic stem cell transplantation developed to allow for the therapy to be extended to a patient population that is unable to tolerate treatment with the conventional procedure due to its toxicity.	ncit:C62714
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	SCT_TBI	Code	Mandatory	A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.	ncit:C15350	_undefined_	_undefined_	_undefined_
PD						No	The non-affirmative response to a question.	ncit:C49487
PD						Yes	The affirmative response to a question.	ncit:C49488
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234


DD	Response
TD	Minimal Residual Disease
TG	One row per subject per mrd analysis method per mrd marker
VD	AGE_AT_MRD_ASSESSMENT	Number	Mandatory	Age of subject (in days) at assessment of minimal residual disease.	ncit:C168855	_undefined_	_undefined_	_undefined_
VD	MRD_METHOD	Code	Mandatory	Modality used to determine minimal residual disease.	ncit:C168933	_undefined_	_undefined_	_undefined_
PD						Flow Cytometry	A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.	ncit:C16585
PD						Molecular Real-Time Quantitative Polymerase Chain Reaction	An application of PCR that measures the products generated during each cycle of the polymerase chain reaction process in order to determine the starting amount of template in the reaction.	ncit:C51962
PD						Next Generation Sequencing	Technologies that facilitate the rapid determination of the nucleotide sequence of large numbers of strands or segments of DNA or RNA.	ncit:C101293
VD	FLOW_CYTOMETRY_TYPE	Code	Mandatory	The classification, nature or purpose for a flow cytometry assay.	ncit:C173732	_undefined_	_undefined_	_undefined_
PD						Leukemia-Associated Immunophenotypes	A technique with leukemia-associated immunophenotypes for counting, examining or sorting microscopic particles suspended in a stream of fluid based on tagging the population of interest with antibody-based reagents.	ncit:C168812
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	MRD_RESULT	String	Mandatory	An assessment of the minimal residual disease response to therapy.	ncit:C124433	_undefined_	_undefined_	_undefined_
VD	MRD_RESULT_NUMERIC	Number	Mandatory	Minimal residual disease value expressed as a percent, fraction or ratio.	ncit:C168951	_undefined_	_undefined_	_undefined_
VD	MRD_RESULT_UNIT	Code	Mandatory	The unit of the minimal residual disease result.	ncit:C173304	_undefined_	_undefined_	_undefined_
PD						%	A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).	ncit:C48570
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998	Note: Only fill in this variable if a numeric result is provided in MRD_RESULT_NUMERIC.
PD						Not Reported	Not provided or available.	ncit:C43234
VD	MRD_SENSITIVTY	Number	Mandatory	Sensitivity of modality used to determine minimal residual disease.	ncit:C168957	_undefined_	_undefined_	_undefined_
VD	MRD_SAMPLE_SOURCE	Code	Mandatory	Source of sample used for minimal residual disease assessment.	ncit:C168958	_undefined_	_undefined_	_undefined_
PD						Bone Marrow	A biological sample containing components collected from bone marrow of an experimental subject.	ncit:C164009
PD						Blood	A small volume of blood removed for testing or storage.	ncit:C41067
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234


DD	Events
TD	Adverse Events
TG	One row per subject per adverse event per avn site per orthopedic procedure per pathogen per gvhd organ
VD	AGE_AT_AE	Code	Mandatory	Age of subject (in days) at the onset of the adverse event.	ncit:C172677	_undefined_	_undefined_	_undefined_
VD	AE_CODE	String	Mandatory	The code of the adverse event.	ncit:C173313	_undefined_	_undefined_	_undefined_
VD	AE_SYSTEM	Code	Mandatory	The name of the system used to grade the adverse events.	ncit:C168872	_undefined_	_undefined_	_undefined_
PD						CTCAE	A standard terminology developed to report adverse events occurring in cancer clinical trials. Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration. The CTCAE contain a grading scale for each adverse event term representing the severity of the event.	ncit:C49704
PD						Balis Neuropathy Scale	An instrument used to grade neurotoxicity occurring in children on a 0-4 scale, where the higher number indicates worse neuropathy.	ncit:C178081
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	AE_SYSTEM_VERSION	String	Mandatory	The version of the adverse event grading system.	ncit:C173314	_undefined_	_undefined_	_undefined_
VD	AE_GRADE	Code	Mandatory	A numeric value corresponding to the degree of severity of an adverse event.	ncit:C166200	_undefined_	_undefined_	_undefined_
PD						Grade 1	An experience that is usually transient, and requires no special treatment or intervention. The event does not generally interfere with usual daily activities. Includes transient laboratory test alterations.	ncit:C41338
PD						Grade 2	An experience that is alleviated with simple therapeutic treatments. The event impacts usual daily activities. Includes laboratory test alterations indicating injury, but without long-term risk.	ncit:C41339
PD						Grade 3	An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.	ncit:C41340
PD						Grade 4	Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.	ncit:C41337
PD						Grade 5	The termination of life associated with an adverse event.	ncit:C48275
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	AE_ATTRIBUTION	Code	Optional	A specific identifiable level (defined qualitatively or quantitatively) of probability of adverse event being caused or associated with the product or procedure administration to a patient.	ncit:C41358	_undefined_	_undefined_	_undefined_
PD						Definite	A characteristic used to qualify the adverse event as certainly related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, occurring in a plausible time relationship to medical intervention, and which cannot be explained by concurrent disease or other interventions. The response to withdrawal of the medical product (dechallenge) should be clinically plausible. The event must be definitive pharmacologically or phenomenologically, using a satisfactory rechallenge procedure if necessary.	ncit:C53260
PD						Probable	Probable adverse event relationship to study product or procedure is defined when there is a clear-cut temporal association between product or procedure administration and adverse event, and a potential alternative etiology of the event is not apparent.	ncit:C41357
PD						Possible	A characteristic indicating that an adverse event may be related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of the drug, but which could also be explained by concurrent disease or other drugs or chemicals. Information on drug withdrawal may be lacking or unclear.	ncit:C53258
PD						Unlikely	A characteristic used to qualify the adverse event as unlikely related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a temporal relationship to the medical intervention which makes a causal relationship improbable, and in which other interventions or underlying disease provide plausible explanations.	ncit:C53257
PD						Unrelated	A characteristic used to qualify the adverse event as clearly not related to the medical intervention.	ncit:C53256
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	AVN_JOINT	Code	Optional	Death of bone tissue in a joint due to temporary or permanent interruption of blood flow.	ncit:C178082	_undefined_	_undefined_	_undefined_	Note: If multiple joints affected, include one observation per joint
PD						Ankle (distal tibia, intrinsic ankle bones)	A gliding joint between the distal ends of the tibia and fibula and the proximal end of the talus.	ncit:C32078
PD						Elbow (distal humerus, proximal radius, proximal ulna)	A type of hinge joint located between the forearm and upper arm.	ncit:C32497
PD						Heel (calcaneus)	The rounded back part of the foot below the ankle and behind the arch.	ncit:C161381
PD						Hip (proximal femur)	A ball-and-socket joint between the head of the femur and the acetabulum.	ncit:C32742
PD						Knee (distal femur, proximal tibia)	A joint connecting the lower part of the femur with the upper part of the tibia. The lower part of the femur and the upper part of the tibia are attached to each other by ligaments. Other structures of the knee joint include the upper part of the fibula, located below and parallel to the tibia, and the patella which moves as the knee bends.	ncit:C32898
PD						Shoulder (proximal humerus)	The region of the body between the neck and the upper arm.	ncit:C25203
PD						Wrist (distal radius, distal ulna, intrinsic wrist bones)	A joint between the distal end of the radius and the proximal row of carpal bones.	ncit:C33894
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
PD						Unknown	Not known, observed, recorded; or reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	AVN_JOINT_LATERALITY	Code	Optional	A finding descriptive of the laterality of the avascular necrosis in the joints.	ncit:C178083	_undefined_	_undefined_	_undefined_
PD						Left	Being or located on or directed toward the side of the body to the west when facing north.	ncit:C25229
PD						Right	Being or located on or directed toward the side of the body to the east when facing north.	ncit:C25228
PD						Bilateral	Affecting both sides of the body or a matched pair of organs.	ncit:C13332
PD						Midline	A medial line, especially the medial line or medial plane of the body (or some part of the body).	ncit:C81170
VD	AVN_METHOD	Code	Optional	The method used to determine the diagnosis of the avascular necrosis.	ncit:C178084	_undefined_	_undefined_	_undefined_
PD						Bone Scan	A nuclear imaging method used to evaluate pathological bone metabolism.	ncit:C17646
PD						CT	A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.	ncit:C17204
PD						MRI (NMR)	Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.	ncit:C16809
PD						X-Ray	A radiographic procedure using the emission of x-rays to form an image of the structure penetrated by the radiation.	ncit:C38101
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
VD	ORTHOPEDIC_PROCEDURE	Code	Optional	Orthopedic procedures to repair avascular necrosis.	ncit:C178085	_undefined_	_undefined_	_undefined_	Note: If multiple procedures performed, include one observation per procedure
PD						Arthroplasty, Hemi/Resurfacing	The trimming and capping of the joint head with ceramic, metal or plastic components and the removal of damaged bone and cartilage within the socket and replacement with a metal shell.	ncit:C178086
PD						Arthroplasty, Total	The removal of the joint head and neck, and replacement with ceramic, metal or plastic components and the removal of damaged bone and cartilage within the socket and replacement with a metal shell.	ncit:C178087
PD						Bone Graft, Free Vascularized	Bone grafts that have their own blood supply.	ncit:C178088
PD						Bone Graft, Nonvascularized	Bone grafts without a blood supply.	ncit:C178089
PD						Chondroplasty	An outpatient procedure to repair damaged cartilage in the knee.	ncit:C178090
PD						Core Decompression	A surgical procedure in which areas of dead bone are drilled to increase blood flow, slow or stop tissue destruction and decrease pressure.	ncit:C157826
PD						Osteotomy	Surgical cutting or removal of bone.	ncit:C51903
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
VD	AE_PATHOGEN	Code	Optional	The pathogen identified as the agent causing the adverse event.	ncit:C185665	_undefined_	_undefined_	_undefined_	Note: If multiple pathogens involved, include one observation per pathogen.
PD						Bacteria	Unicellular, prokaryotic organisms that reproduce by cell division and usually have cell walls; can be shaped like spheres, rods or spirals and can be found in virtually any environment.	ncit:C14187
PD						Virus	An infectious agent which consists of two parts, genetic material and a protein coat. These organisms lack independent metabolism, and they must infect the cells of other types of organisms to reproduce. Most viruses are capable of passing through fine filters that retain bacteria, and are not visible through a light microscope.	ncit:C14283
PD						Fungus	A kingdom of eukaryotic, heterotrophic organisms that live as saprobes or parasites, including mushrooms, yeasts, smuts, molds, etc. They reproduce either sexually or asexually, and have life cycles that range from simple to complex. Filamentous fungi refer to those that grow as multicellular colonies (mushrooms and molds).	ncit:C14209
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998
PD						Not Reported	Not provided or available.	ncit:C43234
VD	INFECTION_CLASSIFICATION	Code	Optional	The type of evidence regarding the infection type.	ncit:C178091	_undefined_	_undefined_	_undefined_
PD						Clinically Documented	Documentation supporting direct medical treatment or testing.	ncit:C178092
PD						Microbiologically Documented Non-Sterile Site	Documentation that supports the site was microbiologically non-sterile.	ncit:C178093
PD						Microbiologically Documented Sterile Site	Documentation that supports the site was microbiologically sterile.	ncit:C178094


DD	Events
TD	Secondary Malignant Neoplasm
TG	One row per subject per secondary malignant neoplasm
VD	AGE_AT_SMN	Number	Mandatory	Age in Days at Secondary Malignant Neoplasm	ncit:C168860	_undefined_	_undefined_	_undefined_
VD	SMN_ICD_O_MORPH	String	Mandatory	SMN ICD-O Morphology Code	ncit:C168862	_undefined_	_undefined_	_undefined_
VD	SMN_ICD_O_TOP	String	Mandatory	SMN ICD-O Topography Code	ncit:C168863	_undefined_	_undefined_	_undefined_


DD	Treatment
TD	Non-Protocol Therapy
TG	One record per subject per non-protocol therapy
VD	NPT_TIMING	Code	Optional	A description of the timing of when the non-protocol therapy was received.	ncit:C175038	_undefined_	_undefined_	_undefined_
PD						After Study Completion	A description of the timing of when the non-protocol therapy was received.	ncit:C175040
VD	NPT_TYPE	Code	Optional	The type of therapy that the patient received outside of the protocol.	ncit:C175041	_undefined_	_undefined_	_undefined_	Note: If multiple non-protocol therapies, include one observation per therapy.
PD						Chemotherapy	The type of therapy that the patient received outside of the protocol.	ncit:C15632
PD						Radiation Therapy	Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.	ncit:C15313
PD						Stem Cell Transplant	A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.	ncit:C15431
PD						Surgery	The branch of medical science that treats disease or injury by operative procedures.	ncit:C17173
PD						Immunotherapy	Therapy designed to induce changes in a patient's immune status in order to treat disease.	ncit:C15262
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649


DD	Disease Attributes
TD	Histology
TG	One row per subject per histologic assessment
VD	AGE_AT_HIST_ASSESSMENT	Number	Optional	Age of subject (in days) at histology assessment.	ncit:C175004	_undefined_	_undefined_	_undefined_
VD	DISEASE_PHASE	Code	Optional	The stage or period of an individual's disease.	ncit:C168878	_undefined_	_undefined_	_undefined_
PD						Initial Diagnosis	The first diagnosis of the individual's condition.	ncit:C156813
PD						Relapse	The return of a disease after a period of remission.	ncit:C38155
PD						Refractory	Not responding to treatment.	ncit:C38014
VD	DISEASE_PHASE_NUMBER	Number	Optional	The number of the disease phase.	ncit:C173258	_undefined_	_undefined_	_undefined_
VD	COURSE	Code	Optional	The type of protocol treatment course administered.	ncit:C168807	_undefined_	_undefined_	_undefined_
PD						Prephase	A chemotherapy treatment administered prior to the definitive chemotherapy treatment.	ncit:C168826
PD						Induction	The first choice of treatment for a particular type of cancer.	ncit:C158876
PD						Intensification	A second round of intense chemotherapy as part of consolidation therapy.	ncit:C173105
PD						Consolidation	Treatment that is given after initial therapy to kill any remaining cancer cells.	ncit:C158876
PD						Stem Cell Transplant Conditioning	A regimen that can be used as a conditioning regimen for hematopoietic stem cell transplantation (HSCT).	ncit:C168794
PD						Maintenance	Continuation of treatment for an extended period of time to prevent relapse.	ncit:C15688
PD						Interim Maintenance	A less intense phase of chemotherapy in between each course of delayed intensification.	ncit:C178069
PD						Delayed Intensification	A repeat of the first two months of induction and consolidation chemotherapy in high-risk and very-high-risk ALL protocols with the goal of eliminating residual drug-resistant cells	ncit:C178270
PD						Continuation	A period in a clinical study during which subjects receive continuation therapy. This therapy is usually different from the therapy given during the induction phase and administered over a longer period of time.	ncit:C123452
PD						Investigational Agent	A new drug or biological drug that is used in a clinical investigation. The term also includes a biological product that is used in vitro for diagnostic purposes.	ncit:C49135
VD	COURSE_NUMBER	Number	Optional	The number assigned to a course of therapeutic agent administration, indicating where a particular course of treatment falls within a sequence of treatments.	ncit:C166235	_undefined_	_undefined_	_undefined_
VD	HIST_ICD_O_MORPH	String	Optional	Codes for the histologic type of the tumor being reported using ICD-O.	ncit:C176985	_undefined_	_undefined_	_undefined_
